GILEAD SCIENCES, INC. Deferred Tax Liabilities, Intangible Assets
GILEAD SCIENCES, INC. (GILD) had Deferred Tax Liabilities, Intangible Assets of $3.21 billion as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets · last filed 2026-02-24
- 2025-12-31: Deferred Tax Liabilities, Intangible Assets $3.21B.
- 2024-12-31: Deferred Tax Liabilities, Intangible Assets $3.84B.
- 2023-12-31: Deferred Tax Liabilities, Intangible Assets $5.48B.
- 2022-12-31: Deferred Tax Liabilities, Intangible Assets $5.73B.
| Period end | Deferred Tax Liabilities, Intangible Assets | Deferred Tax Liabilities, Intangible Assets as first filed |
|---|---|---|
| 2025-12-31 | $3.21B 10-K · filed 2026-02-24 | |
| 2024-12-31 | $3.84B 10-K · filed 2026-02-24 | |
| 2023-12-31 | $5.48B 10-K · filed 2025-02-28 | |
| 2022-12-31 | $5.73B 10-K · filed 2024-02-23 | |
| 2021-12-31 | $6.72B 10-K · filed 2023-02-22 | |
| 2020-12-31 | $6.17B 10-K · filed 2022-02-23 | |
| 2019-12-31 | $1.40B 10-K · filed 2021-02-25 | |
| 2018-12-31 | $1.66B 10-K · filed 2020-02-25 | $1.67B 10-K · filed 2019-02-26 |
| 2017-12-31 | $1.32B 10-K · filed 2019-02-26 | |
| 2016-12-31 | $104.00M 10-K · filed 2018-02-27 | |
| 2015-12-31 | $280.00M 10-K · filed 2017-02-27 | |
| 2014-12-31 | $328.00M 10-K · filed 2016-02-24 | |
| 2013-12-31 | $368.00M 10-K · filed 2015-02-25 | $368.12M 10-K · filed 2014-02-25 |
| 2012-12-31 | $306.35M 10-K · filed 2014-02-25 | |
| 2011-12-31 | $330.18M 10-K · filed 2013-02-27 | |
| 2010-12-31 | $322.17M 10-K · filed 2012-02-23 | |
| 2009-12-31 | $384.48M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |